1. ACUTE LEUKEMIA 2012-2013

2. Leukemia Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and / or peripheral blood

3. Classification Classified based on cell type involved and the clinical course –Acute : ALL AML –Chronic : CLL CML

4. Acute Leukemias Acute leukemias are clonal malignant hematopoietic disorders resulting from genetic alterations in normal hematopoietic stem cells. These alterations disrupt normal differentiation and/or cause excessive proliferation of abnormal immature “leukemic” cells or “blasts.” As the disease progresses, leukemic cells accumulate in the bone marrow, blood, and organs, displacing normal progenitor cells and suppressing normal hematopoiesis

5. Acute Leukemia - Essentials Short course of symptoms Fatigue, fever, easy bruising, bleeding Cytopenias - or pancytopenia More than 20% blasts in bone marrow Blasts in peripheral blood in 90% cases

6. AL - EPIDEMIOLOGY The frequency of AL varies between 1 and 6,5 cases to 100.000 population each year. The frequency of AL varies with subtype and age. AL represents 10% of the neoplastic diseases and is the principal cause of neoplastic for ages 0-35 years.

7. ALL - Epidemiology Approximately 3,000 new cases per year children peak age 4 years Mostly affects children, accounts for 2/3 of childhood leukemia (peak age 4 years) Comprises less than 20% of leukemia in young adults May be B-cell, T-cell, or null-type (non-B, non-T cell) Only 20-40% of adults with ALL are cured with current regimens.

8. AML - Epidemiology 2.3 per 100,000 people per year Higher among men than women (2.9 vs 1.9). The difference is even more apparent in older patients. Most common leukemia in adults (80% of cases) 65 years or older Vast majority of patients 65 years or older AML is more common in whites than in other populations.

9. ALL - Etiology Uncertain, but several proposed linkages: · Genetic - Philadelphia chromosome · Viral infection (EBV, HIV) · Exposure to high energy radiation (T-cell ALL) · Toxic chemical exposure · Smoking

10. AML - Etiology Primary AML –Increased incidence Genetic fragility –Bloom syndrome –Faconi anemia –Wiskott Aldrich –Down, Klinefelter, Patau syndromes tobacco use? herbicides?, pesticides? benzene exposure Secondary AML –XRT –Topoisomerase II inhibitors (e.g etopisode), alkylating agents –MDS –other cell proliferation disorders CML, polycythemia vera, primary thrombocytosis, PNH

11. Clinical features General : Onset is abrupt & stormy (usually present within 3 months) –Bone marrow failure (anemia, infection,bleeding) –Bone pain & tenderness

12. Clinical presentation : Will present with sign or symptoms related to : –Pancytopenia:  WBC  infection  infectious syndrome  Hb  anemia  anemic syndrome  Platelets  bleeding – hemorragic syndrome –Organ infiltration  tumoral syndrome Lymphadenopathy. Splenomegally. Hepatomegally. CNS:5-10% of patient with ALL More common with ALL than AML.

13. Clinical features - specials L mediastinal tumoral mass L CNS infiltration M2 : Chloroma:-presents as a mass lesion ‘tumor of leukemic cells’ M3 : DIC M4/M5 : Infiltration of soft tissues, gum infiltration, skin deposits,Meningeal involvement-headache, vomiting, eye symptoms

14. Gingival Infiltration in Monocytic (AML M4 eos) Variant of AML Mani, A, Lee, DA. Leukemic Gingival Infiltration. N Engl J Med 2008; 358(3): 274. Copyright ©2008 Massachusetts Medical Society

15. Gum hypertrophy

16. A B C Chloromas NEJM 1998

17. Clinical symptoms/Physical Findings Extramedullary disease (ie, myeloid sarcoma) –Can also have involvement of lymph nodes, intestine, mediastinum, ovaries, uterus

18. Clinical features - specials

19. Skin Infiltration with AML (Leukemia Cutis)

20. Leukostasis Leukostasis – predominantly in those with WBC counts > 100,000 (10% of patients); can also be seen in patients with WBC > 50,000 –Most common in those with M4 or M5 leukemia –Function of the blast cells being less deformable than mature myeloid cells. As a result, intravascular plugs develop. –High metabolic activity of blast cells and local production of various cytokines contribute to underlying hypoxia

21. Leukostasis Thornton, KA, Levis, M. FLT3 Mutation and Acute Myelogenous Leukemia with Leukostasis. N Engl J Med 2007; 357:1639. Copyright ©2007 Massachusetts Medical Society

22. Leukostasis Common symptoms –Pulmonary: dyspnea, chest pain –CNS: headaches, altered mentation, CN palsies, ocular symptoms –Priapism –Myocardial Infarction

23. Acute leukemia - Diagnosis –Lab evaluation The lab diagnosis is based on two things –Finding a significant increase in the number of immature cells in the bone marrow including blasts, promyelocytes, promonocytes (>30% blasts is diagnostic) –Identification of the cell lineage of the leukemic cells

24. Investigations CBC: –60% of pts have an elevated WBC. –Most are anemic –Most are thrombocytopenic –90%have blast in the periphral blood film. electrolytes: –Hypo/hyper kalemia –Hypomagnesimia –hyperphosphatemia Hypermetabolism: –  LDH. –  uric acid. DIC: –Most common with promyelocytic leukemia,small% monocytic leukemia&ALL Bone marrow biopsy and aspirate: –30%or more of all nucleated cells are blast. Radiology: –CXR:mediastinal mass(T-cell ALL) –Osteopenia or lytic lesion 50% of patients with ALL.(itractable pain).

25. Acute leukemia - Diagnosis –Peripheral blood: Anemia (normochromic, normocytic) Decreased platlets Variable WBC count –The degree of peripheral blood involvement determines classification: »Leukemic – increased WBCs due to blasts »Subleukemic – blasts without increased WBCs »Aleukemic – decreased WBCs with no blasts

26. Acute Leukemias - CBC Hb – 5,6 g/dl Plt – 15.000/mmc WBC – 34.000/mmc –PN – 10% –L - 6% –M – 3% –Bl – 81% Hb – 3,5 g/dl Plt – 5.000/mmc WBC – 1.500/mmc –PN - 15% –L – 80% –M – 5%

27. Acute leukemia - Diagnosis Bone marrow aspirate & trephine: Hypercellular,, –blast cells ( > 20%), –presence of Auer rods - AML type Cytochemistry : Special stains to differentiate AML from ALL ; Positivity with Sudan black & Myeloperoxidase (MPO) in AML

28. Jemshidi trephine & Salah aspiration needle

29. Acute leukemia - Diagnosis Diagnosis and classification of the immature cells involved may be done by : –Morphology –Cytochemistry –Immunophenotyping –Cytogenetic

30. Classification Criteria: - Morphology :apperance of cell under microscope. - Cytochemistry:chemical activity of the cell. (myeloperoxidase, Sudan Black B) - immunophenotyping: antigen pressent in the cell membrane - Cytogenetics: chromosome of the cell - Molecular biology: Classification: 3 groups of acute leukemias: - acute myeloid leukemias AML(M1 –M6). - acute lymphoblastic leukemias ALL (L1-L3). - Biphenotypic leukemias or Acute undifferentiated leukemia

31. Diagnosis Morphologic –French American British Classification L1: small uniform blasts (pediatric ALL) L2: larger, more variable sized blasts (adult ALL) L3: uniform cells with basophilic and sometimes vacuolated cytoplasm (mature B cell ALL)

32. L1 - 85% of childhood ALL L2 - Majority of adult ALL L3 - Includes Burkitt’s. < 5% of ALL

33. ALL – L1/periferal blood smear

34. ALL – L2/periferal blood smear

35. ALL3/bone marrow smear

36. FAB Classification of AML M0 undifferentiated acute myeloblastic leukemia (5%) M1 AML with minimal maturation (20%) M2 AML with maturation (30%) – t(8;21) M3 Acute promyelocytic leukemia (5%) –t(15;17) M4 Acute myelomonocytic leukemia (20%) M4 eos Acute myelomonocytic leukemia with eosinophilia (5%) –inv (16) M5 Acute monocytic leukemia (10%) –t(9;11) M6 Acute erythroid leukemia (3%) M7 Acute megakaryoblastic leukemia (3%)

37. WHO Classification AML with certain genetic abnormalities –t(8;21), t(16), inv(16), chromosome 11 changes –t(15;17) as usually seen with AML M3 AML with multilineage dysplasia (more than one abnormal myeloid cell type is involved) AML related to previous chemotherapy or radiation AML not otherwise specified –undifferentiated AML (M0) –AML with minimal maturation (M1) –AML with maturation (M2) –acute myelomonocytic leukemia (M4) –acute monocytic leukemia (M5) –acute erythroid leukemia (M6) –acute megakaryoblastic leukemia (M7) –acute basophilic leukemia –acute panmyelosis with fibrosis –myeloid sarcoma (also known as granulocytic sarcoma or chloroma) Undifferentiated or biphenotypic acute leukemias (leukemias that have both lymphocytic and myeloid features. Sometimes called ALL with myeloid markers, AML with lymphoid markers, or mixed lineage leukemias.)

38. AML2 – bone marrow smear

39. AML3 – bone marrow smear

40. Prognosis in ALL parametersGoodpoor WBClow High(>50x10 9 /l) GenderGirlsBoys ImmunophenotypeC-ALLB-ALL AgeChild Adult or infant. CytogeneticNormal,hyperdiploid, Ph+,11q23rearrangeme nts. Time to clear blast from blood < 1week >1week Time to remission<4weeks>4weeks Cns disease at presentationAbsentPresent Minimal residual disease. Negative at 1-3 months Still positive at 3-6 months.

41. Prognosis in ALL Good risk includes –(1) no adverse cytogenetics, –(2) age younger than 30 years –(3) WBC count of less than 30,000/mL, and –(4) complete remission within 4 weeks. Intermediate risk –does not meet the criteria for either good risk or poor risk. Poor risk includes –(1) adverse cytogenetics [(t9;22), (4;11)], –(2) age older than 60 years, –(3) precursor B-cell WBCs with WBC count greater than 100,000/mL, or –(4) failure to achieve complete remission within 4 weeks.

42. Prognosis in AML Prognostic Factors: Age at diagnosis Comorbidities (acute vs chronic) Chromosomal findings Symptomatic interval preceding diagnosis Presenting Leukocyte count Circulating myeloblast count FAB classification Morphologic characteristics of the leukemic cell

43. Treatment of acute leukemias Choice of Rx is influenced by: type (AML vs ALL) age curative vs palliative intent

44. Principles of treatment combination chemotherapy –first goal is complete remission –further Rx to prevent relapse supportive medical care –transfusions, antibiotics, nutrition psychosocial support –patient and family

45. Supportive measures: -isolation in positive laminer flux room -insertion of central line -family and patient support by permanent social worker -Alkaline diuresis to prevent tumor lysis syndrome -oropharynx/GIT decontamination to prevent fungal infection -IV antibiotics for infection -Blood transfusion if anemia and thrombocytopenia.

47. Chemotherapy for acute leukemias Phases of ALL treatment –induction –intensification –CNS prophylaxis –maintenance Phases of AML treatment –induction –consolidation (post-remission therapy) post-remission therapy

48. ALL Treatment 1 – Remission Induction 2 – Intensification (Consolidation) Therapy 3 – Maintenance Therapy 4 – CNS Prophylaxis 5 – Allogeneic Stem Cell Transplant

49. ALL Treatment Remission Induction –Goals: restore normal hematopoiesis, induce a complete remission rapidly in order to prevent resistance to drugs –Standard induction regimen 4 or 5 drugs: vincristine, prednisone, anthracycline, L-asparaginase, +/- cyclophosphamide –80-90% complete remission Intensification –High doses of multiple agents not used during induction or re- administration of the induction regimen

50. ALL Treatment Maintenance Therapy –Daily po 6MP, weekly MTX, monthly pulses of vincristine and prednisone for 2-3 yrs CNS Prophylaxis –Given during induction and intensification –Intrathecal: MTX, Cytarabine, corticosteroids –Systemic: high dose mtx, cytarabine, L-asparaginase –+/- Cranial Irradiation

51. ALL Treatment Stem Cell Transplant –Done during first CR –Indications: Ph Chromosome t(4;11) mutation Poor initial response to induction therapy Other –Adolescents benefit significantly from pediatric ALL regimens vs. adult regimens

52. AML Treatment Remission induction therapy –Commonly anthracycline (ie, daunorubicin, idarubicin) and cytarabine → (“3+7 regimen”) Cytarabine has ample CNS penetration so no need for prophylactic intrathecal chemotx (also, ↓ risk in patients with AML compared to ALL) 60-80% achieve complete remission Postremission therapy 1.Consolidation –longer survival than maintence alone –typically high dose cytarabine 2.Maintenance – continue chemotx monthly for 4-12 months –nonmyelosuppressive doses

53. COMPLICATIONS TREATMENT

54. Tumor Lysis Syndrome Characterized by metabolic derangements caused by massive release of cellular components following lysis of malignant cells Commonly seen in malignancies with high rates of cell proliferation (esp. ALL, Burkitt’s lymphoma); also can be seen with AML

55. Tumor Lysis Syndrome Tumor lysis syndrome - hyperphosphatemia, hyperkalemia, hyperuricemia, hypocalcemia and uremia –Retrospective study of 788 patients (433 adults) found incidence of hyperuricemia and TLS to be 14.7%/3.4% in patients with AML compared to 21.4%/5.2% in patients with ALL and 19.6%/6.1% in patients with NHL Electrolyte abnormalities can occur without the entire spectrum of TLS or even before tx is initiated –Hyperuricemia –Lactic acidosis

56. Tumor Lysis Syndrome Release of intracellular proteins →catobilized to hypoxanthine → xanthine → uric acid → Crystalization of uric acid and in renal tubules → impaired renal function Release of phosphate from malignant cells → calcium phosphate precipitation and further renal impairment along with hypocalcemia and resultant symptoms from ↓Ca –Hyperphosphatemia: nausea, vomiting, diarrhea, seizures, lethargy –Hypocalcemia: arrhythmia, hypotension, tetany, cramps –Hyperkalemia: arrhythmia, cramps, paresthesia

57. Tumor Lysis Syndrome Prevention and management –IV hydration : promotes excretion of uric acid and phosphate; improves renal blood flow/GFR –Allopurinol → competitive inhibitor for xanthine oxidase. Therefore, ↓ conversion of purine metabolites to uric acid However, must consider buildup of xanthine crystals → acute obstructive uropathy (HYDRATE!!!) –Recominant urate oxidase (rasburicase) Promotes conversion of uric acid to allantoin (highly soluble; urinary excretion) Indicated in patients at high risk of TLS (Burkitt’s Lymphoma, B-ALL, ALL (WBC >100,000), AML (WBC >50,000) Also indicated in patients that develop hyperuricemia despite allopurinol –Dialysis can be used in severe cases –Urine alkalization is NOT recommended – does not increase solubility of xanthine/hypoxanthine with an increased propensity to develop xanthine- obstructive uropathies (esp with allopurinol use)

58. DIC Common symptoms/findings – in addition to weakness (anemia), infections/fever (malfunctioning WBCs) –petechiae, ecchymoses, hematuria, bleeding from venipuncture sites –migratory thrombophlebitis (Trousseau’s syndrome) –nonbacterial thrombotic (marantic) endocarditis –DVT/PE Lab findings –Prolonged PT/INR, PTT –microangiopathic anemia (schistocytes) –thrombocytopenia –elevated fibrin split products –elevated D-dimer –low fibrinogen

59. DIC Treatment 1.Supportive therapy Platelets Cryoprecipitate (fibrinogen) FFP 2.Treatment for obvious thrombosis (e.g thrombophlebitis, mural thrombus) UFH or LMWH; often resistant to coumadin activated protein C 3.Treatment of underlying malignancy In the case of AML M3 → All-Trans Retinoic Acid (PML-RARα) –Induces differentiation beyond promyelocyte phase –Only with the more common t(15;17) translocation; t(11;17) and t(5;17) do not respond to ATRA Remission rates of greater than 90% with AML M3 patient treated with ATRA and chemotx (eg, anthracyclines (idarubicin)) with 60-70% disease free survival Arsenic trioxide in those that relapse – achieves complete remission in >90%

60. CNS Involvement Occurs in less than 5% of AML patients (highest incidence in relapsed promyelocytic (M3) variant) –Routine LP is not performed unless symptoms suggestive of CNS pathology Common symptoms –headache –mental status changes –CN palsies (commonly CN III or VI) –CSF findings blast cells moderate increase in protein and moderate decrease in glucose

61. CNS Involvement Treatment –Intrathecal chemotherapy (methotrexate or cytarabine) +/- whole brain XRT addition of XRT depends on response to intrathecal chemotx and whether there is cranial nerve involvement high relapse rate –Commonly administer prophylactic intrathecal chemotx in relapsed promyelocytic disease